

Systemic Viral Delivery of Potent RNA Therapeutics to Hard-to-Treat Cancers




The Need

- ❑ Unmet clinical need: late-stage cancers
- ❑ IO unresponsive ~80B\$ solid tumors market
- ❑ Efficacy limited by systemic toxicity
- ❑ Cytokines work → but can't be safely delivered
- ❑ Viral vectors lack tumor specificity
- ❑ Most viral dose is sequestered by normal tissue

Our Solution: Tumor-Targeted Viral Platform

- ❑ Native viral vector + external engager
- ❑ No coat engineering → full potency retained
- ❑ IV-ready vector
- ❑ Tumor-marker gated entry
- ❑ Programmable payloads: cytokines, immune modulators, checkpoint inhibitors
- ❑ Modular-rapid retargeting across indications

Technology



Pipeline: Expansion-ready

Candidate	Discovery	Lead Opt	Preclinical	Phase 1	Phase 2	Phase 3
VRBx-001 (CEACAM6 Solid tumors)	█	█				
VRBx-002 (PSMA Prostate)	█	█				
VRBx-003 Novel Targets	█					

Lead Target: CEACAM6

- ❑ 80-90% of solid tumors (Pancreatic, Lung, Ovarian, Colorectal)
- ❑ Poor prognosis marker

IP & Development Status

- ❑ 2 Patents from Weizmann institute of science, TS discussions
- ❑ Next IP: viral cassette payloads
- ❑ Initial POC in-vitro, supportive in-vivo
- ❑ External in-vitro and in-vivo validation

CEO



Dr. Diana Gataulin

Co-inventor
Therapeutic dev.
B D & Strategy

CSO



Dr. Eyal Zoler

Virology & cytokine
engineering expert

SCIENTIFIC ADVISOR



Prof. Menachem Rubinstein

Core technology
inventor; creator of
Roferon-A™, Rebif™
Enbrel™

Ask & Funds Allocation

- ❑ \$200K Angel bridge for Candidate Selection (6m)
- ❑ 2-2.5M\$ Pre Seed (24m)
- ❑ Two Tranches:
Tranche 1 (1M): Candidate Optimization and Nomination
Tranche 2 (1-1.5M\$): Early Safety and CMC, Pre-IND

Summary

Selective tumor killing
Safe | Flexible | Shielded

Contact

virobixcompany@gmail.com

www.virobix.com

Supporters and traction:



PEARL COHEN

